Biology Reference
In-Depth Information
[7] Zimmerman Z, Jones M, Shatry A, Komatsu M, Mammolenti M, Levy R. Cytolytic
pathways used by effector cells derived from recipient naive and memory T cells and
natural killer cells in resistance to allogeneic hematopoietic cell transplantation. Biol
Blood Marrow Transplant 2005;11(12):957-71.
[8] Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and
expanding options for immunomodulation: an update. Blood 2010;115(19):3861-8.
[9] Antin JH. Acute graft-versus-host disease: inflammation run amok? J Clin Invest
2001;107(12):1497-8.
[10] Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute
graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone
marrow transplantation. Blood 2000;95(9):2754-9.
[11] Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccha-
ride-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J
Exp Med 1992;175(2):405-13.
[12] Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effec-
tor of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med
1987;166(5):1280-9.
[13] Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and
graft-versus-host disease. Blood 2005;105(11):4191-9.
[14] Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol
2006;43(1):3-10.
[15] Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside.
Blood 2009;114(20):4327-36.
[16] Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, et al. LPS antagonism
reduces graft-versus-host disease and preserves graft-versus-leukemia activity after
experimental bone marrow transplantation. J Clin Invest 2001;107(12):1581-9.
[17] Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al.
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first
remission: a randomized trial of two irradiation regimens [see comments]. Blood
1990;76(9):1867-71.
[18] Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, et al. Alloge-
neic marrow transplantation in patients with chronic myeloid leukemia in the chronic
phase: a randomized trial of two irradiation regimens. Blood 1991;77(8):1660-5.
[19] Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus
cyclophosphamide compared with total-body irradiation plus cyclophosphamide be-
fore marrow transplantation for myeloid leukemia: long-term follow-up of 4 random-
ized studies. Blood 2001;98(13):3569-74.
[20] Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical
and clinical results. Semin Oncol 2000;27(2 Suppl. 5):78-81.
[21] Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoi-
etic chimerism in DLA-identical littermate dogs given sublethal total body irradiation
before and pharmacological immunosuppression after marrow transplantation. Blood
1997;89(8):3048-54.
[22] Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, et al. Synergism
between mycophenolate mofetil and cyclosporine in preventing graft-versus-host
disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow
grafts. Blood 1998;91(7):2581-7.
[23] Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al.
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic
stem cell transplantation. Blood 2003;102(2):756-62.
[24] Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1
blockade does not prevent acute graft-versus-host disease: results of a random-
ized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in
allogeneic bone marrow transplantation. Blood 2002;100(10):3479-82.
[25] Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, et al. Kerati-
nocyte growth factor separates graft-versus-leukemia effects from graft-versus-host
disease. Blood 1999;94(2):825-31.
[26] Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor
administered before conditioning ameliorates graft-versus-host disease after allogeneic
bone marrow transplantation in mice. Blood 1998;92(10):3960-7.
[27] Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al. Phase 1/2
randomized, placebo-control trial of palifermin to prevent graft-versus-host disease
(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood
2006;108(9):3216-22.
[28] Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-
host disease and graft-versus-leukemia. Blood 2007;110(1):9-17.
13
Search WWH ::
Custom Search